# US 8,278,312 B2 · Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,312 B2
- Document ID: US8278312B2
- Status: Granted
- Kind: B2
- Application number: 12/682,316
- Filed: 2008-09-13
- Published: 2010-09-30
- Granted: 2012-10-02
- Earliest claimed: 2007-10-11
- Assignees: Merck Patent GmbH
- Inventors: Markus Klein; Werner Mederski; Christos Tsaklakidis; Norbert Beier
- Web page: https://patentgrep.com/patent/US8278312B2

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/10: for osteoporosis
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.

## Claims

### Claim 1

A compound selected from the following compounds A1 to A27:
No.
Structure and/or name
“A1”
2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
2-yl]phenoxy}acetamide
“A2”
2-{2-[3-(2,6-Dimethylphenylamino)-5,7-dimethylimidazo-
[1,2-a]pyrimidin-2-yl]phenoxy}acetamide
“A3”
(2,6-Dichlorophenyl)-{2-[2,4-dimethoxy-6-(5-methylamino-
1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}-
amine
“A4”
(2,6-Dichloro-4-fluorophenyl)-{2-[2,4-dimethoxy-6-(5-
methylamino-1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]-
pyrimidin-3-yl}amine
“A5”
(2,6-Dichlorophenyl)-{2-[2-(5-ethylamino-1,3,4-oxadiazol-2-
yl)-4,6-dimethoxyphenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A6”
5-{2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3,5-dimethoxyphenyl}-3H-1,3,4-oxadiazol-2-one
“A7”
2-{2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3-ethylphenoxy}acetamide
“A8”
2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3-ethylphenoxy}acetamide
“A9”
2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3-ethyl-5-methoxyphenoxy}acetamide
“A10”
2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-5-methoxy-3-methylphenoxy}acetamide
“A11”
{2-[2,4-Dimethoxy-6-(5-methylamino-1,3,4-oxadiazol-2-yl)-
phenyl]imidazo[1,2-a]pyrimidin-3-yl}-(2,6-dimethylphenyl)-
amine
“A12”
2-{2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-
2-yl]-3-ethyl-5-methoxyphenoxy}acetamide
“A13”
(2,6-Dichloro-4-fluorophenyl)-{2-[2-(5-methylamino-1,3,4-
oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A14”
(2,6-Dichlorophenyl)-{2-[2-(5-methylamino-1,3,4-oxadiazol-
2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A15”
(2,6-Dichlorophenyl)-{2-[2-(5-ethylamino-1,3,4-oxadiazol-2-
yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A16”
{2-[2,4-Dichloro-6-(5-methylamino-1,3,4-oxadiazol-2-yl)-
phenyl]imidazo[1,2-a]pyrimidin-3-yl}-(2,6-dimethylphenyl)-
amine
“A17”
2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-2-
yl]-3,5,N-trimethoxybenzamide
“A18”
2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-2-
yl]-3,5-dimethoxybenzohydrazide
“A19”
{2-[2-Chloro-6-(5-methylamino-1,3,4-oxadiazol-2-yl)phenyl]-
imidazo[1,2-a]pyrimidin-3-yl}-(2,6-dimethylphenyl)amine
“A20”
Methyl 3-chloro-2-[3-(2,6-dimethylphenylamino)imidazo-
[1,2-a]pyrimidin-2-yl]benzoate
“A21”
(2,6-Dimethylphenyl)-{2-[4-methoxy-2-(5-methylamino-
1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}-
amine
“A22”
{2-[2-Chloro-6-(5-methylamino-1,3,4-oxadiazol-2-yl)phenyl]-
imidazo[1,2-a]pyrimidin-3-yl}-(2-chloro-6-methylphenyl)-
amine
“A23”
(2,6-Dichloro-3-methylphenyl)-{2-[2,4-dimethoxy-6-(5-
methylamino-1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]-
pyrimidin-3-yl}amine
“A24”
2-[3-(2,6-Dichloro-3-methylphenylamino)imidazo[1,2-a]-
pyrimidin-2-yl]-N-ethyl-3,5-dimethoxybenzamide
“A25”
(3,5-Dimethylisoxazol-4-yl)-{2-[2-(5-methylamino-1,3,4-
oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
“A26”
(2-Chloro-6-methylphenyl)-{2-[2-fluoro-6-(5-methylamino-
1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}-
amine
“A27”
(4-Fluoro-2,6-dimethylphenyl)-{2-[2-fluoro-6-(5-methyl-
amino-1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-
3-yl}amine
or a pharmaceutically usable salt or stereoisomer thereof, including mixtures thereof in all ratios.

### Claim 2 (depends on 1)

A medicament composition comprising at least one compound according to claim 1 or a pharmaceutically usable salt or stereoisomer mixture thereof in all ratios, and optionally excipients and/or adjuvants.

### Claim 3 (depends on 1)

A method for treating a patient suffering from type 1 or type 2 diabetes comprising administering to said patient a compound according to claim 1 or a pharmaceutically usable salt or stereoisomer thereof.

### Claim 4 (depends on 1)

A method of lowering blood sugar in a patient comprising administering to said patient a compound according to claim 1 or a pharmaceutically usable salt or stereoisomer thereof.
